Lexology March 25, 2024
Ropes & Gray LLP

Click here to listen to the audio.

In this second installment of Ropes & Gray’s three-part podcast series exploring recent regulatory, compliance, and enforcement developments in the fraud, waste, and abuse space and the potential implications for health care and life science companies in 2024, health care partners Devin Cohen and Michael Lampert are joined by litigation & enforcement partner Andrew O’Connor for a conversation on remuneration offered and paid by labs. Topics of discussion include an exploration of the permissibility of specimen processing arrangements, and an examination of overlay between the Office of the Inspector General (“OIG”) advisory opinions and Department of Justice (“DOJ”) enforcement actions.

Transcript:

Devin Cohen: Hello, and welcome to today’s podcast. This is part two...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Conferences / Podcast, Govt Agencies, OIG, Provider, Trends
HHS-OIG Highlights Anti-Fraud Safeguards of Drug Manufacturer’s Free Drug Program for Patients in Financial Need
Putting infection control to the test
HHS OIG Finds Favorably for Free Access to Pharmaceutical Product
FDA’s Recent Guidance on Accelerated Approval and Implications for Rare Diseases
Medicare Part D Spending on 10 Diabetes Drugs Hit $35.8B in 2023

Share This Article